Opdivo (Bristol Myers Squibb) is expected to face US biosimilar competition from 2028. BMS guides to US biosimilar entry from 2028. Subcutaneous Opdivo Qvantig may extend the franchise.
Opdivo's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Opdivo is 21% of Bristol Myers Squibb's 2025 revenue ($10.1B of $48.2B). With Pomalyst and Eliquis, the drugs tracked here add up to 56% of Bristol Myers Squibb's revenue losing US exclusivity by 2028.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Opdivo is highlighted.